TYRATyra Biosciences, Inc.
$19.91+59% 1Y
$19.91
$12.5452 weeks$39.61
TYRA as reported
- Net income
- −$149M
Net income · +40% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$110M
Free cash flow · +27% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.39
EPS · +34% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$149M | +40% | Q2 2026 |
| EPS | −$2.39 | +34% | Q2 2026 |
| ROE | −40% | n/a | Q2 2026 |
| ROA | −38% | n/a | Q2 2026 |
| Free cash flow | −$110M | +27% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Tyra Biosciences, Inc. (TYRA) · Net incomeNet incomeTyra Biosciences, Inc. (TYRA)
On our screens:Most shorted stocks